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work/productivity was measured by the validated Work Productivity and Activity
Impairment (WPAI) instrument. MRUwasmeasured by traditional health care pro-
vider, emergency room (ER) visits and hospitalization in the past 6 months. Com-
parisons were made between respondents who reported as diagnosed with AS
(excluding other auto-immune diseases) vs. respondents without AS (non-AS
group).RESULTS:Of 19,954 survey respondents, 52 (0.26%)were diagnosedwithAS.
The average age was 43.0 (SD 13.5) years with 57.7% of males. AS group reported
higher Charlson comorbidity index score than in non-AS group (1.4 vs. 0.2). The
most common comorbidities (25% of patients) were headache, insomnia, gingi-
vitis, body pain, sleep difficulties, arrhythmia, anxiety and arthritis. AS group had
lower mean scores of PCS (42.9 vs. 49.6) and MCS (44.1 vs. 46.2), more patients
visited health care providers (71.2% vs. 49.7%), ER (30.8% vs. 17.6%) and hospitalized
(19.2% vs. 5.7%) in the past 6 months vs. non-AS group. Also, AS group reported
more work productivity loss (absenteeism/presenteeism) with 40.1% vs. 23.3% and
impairment in daily activity with 36.7% vs. 20.3% in non-AS group. All comparisons
between AS and non-AS groups were statistically significant at P 0.05, except
MCS. CONCLUSIONS: From the China NHWS results, AS patients suffer from im-
pairment in quality of life, work/productivity loss, more co-morbidities and use of
medical services. The findings indicate there is still an unmet medical need in AS
patients in China.
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OBJECTIVES: To compare patient-reported outcomes (PROs) achieved with sus-
tained, reduced, or suspended etanercept (ETN) in combination withmethotrexate
(MTX) over 52 weeks after induction of sustained response with combination ETN/
MTX therapy in a sub-analysis of the developing countries from the multinational
PRESERVE trial.METHODS:Data from9developing countries of Asia, Latin America
and Europe were included in this sub-analysis. Patients with moderately active RA
(DAS28 of 3.2 and 5.1) who achieved DAS28 low disease activity (LDA; DAS28
3.2; average Weeks12–36 and at Week 36) during the 36-week open-label induc-
tion phase with ETN 50mg QW plus MTX (E50/M) were randomized to double-blind
treatment with E50/M, ETN 25mg QW plus MTX (E25/M), or placebo plus MTX (P/M)
for an additional 52 weeks. PROs included Health Assessment Questionnaire
(HAQ), EuroQol-5D (EQ-5D), Functional Assessment of Chronic Illness Therapy
(FACIT), Medical Outcomes Study sleep problem index II (MOS), and Brief Pain
Inventory (BPI). RESULTS:Of 491 patients enrolled, 388 were randomized blindly at
Week 36: E50/M (n127), E25/M (n134), or P/M (n127). Significant improvement
from baseline (P0.0001) in all PROswas observedwith E50/M atWeek 36. Adjusted
mean changes in HAQ, EQ-5D, BPI and MOS from Weeks 36–88 were statistically
significantly smaller with E50/M and E25/M versus P/M (P0.05), indicating less
deterioration. Adjusted mean change in FACIT was significantly smaller for E50/M
but not E25/M versus P/M (P0.05). A higher percentage of patients in the E50/M
(57.5%) and E25/M (56.0%) groups had a HAQ 0.5 compared to those in the P/M
group (43.3%) at Week 88 (P0.05). CONCLUSIONS: In patients with moderate RA,
after induction and maintenance of LDA, ETN full- and reduced-dose regimens
were superior to step-down treatment with MTX alone in their effects on func-
tional and quality of life endpoints. Minimal differences in PROs were observed
between the full- and reduced-dose treatment groups.
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OBJECTIVES: The objective of the present investigation was investigation of com-
parative clinical outcome profile and cost effectiveness of DMARDs, NSAIDs, ste-
roid steroids, herbal drugs.METHODS: It was prospective, longitudinal, open label,
parallel group study consisting of four groups with 40 patients in each cohort. The
patients were grouped according to the treatment received (DMARDs, NSAIDs,
steroid steroids, IL-1 inhibitors). The data regarding health outcomeand costswas
assessed before and after the threemonth regimenusingHAQDI, DAS -28, VAS and
EQ5D3L and case report form. RESULTS: The mean change in scores of patients
subjected to HAQ DI was 0.54 in DMARD; 0.46 in NSAID; 0.50 in steroid drug treated
and 0.63 in IL-1 inhibitor treated cohorts. The mean change in scores of patients
subjected to DAS-28 was 0.54 in DMARD; 0.52 in NSAID; 0.79 in steroid drug treated
and 1.39 in IL-1 inhibitor treated cohorts. The mean change in scores of patients
subjected to VAS was 15 in DMARD; 11 in NSAID; 2.4 in steroid drug treated and 39
in IL-1 inhibitor treated cohorts. Themean change in scores of patients subjected
to EQ5D3L was 0.26 in DMARD; 0.41 in NSAID; 0.39 in steroid drug treated and 0.72
in IL-1 inhibitor treated cohorts. The mean values varied significantly among all
the groups (p0.01). The average cost effectiveness was 331.48 for DMARD; 206.52
for NSAID; 224.32 for steroid drug treated and 188.41 for IL-1 inhibitor treated
cohorts. The QALDs in each treatment groupwhichwas 18 in DMARD; 15 in NSAID;
12 in steroid drug treated and 25.5 in IL-1 inhibitor treated cohorts. The incremen-
tal cost effectiveness ratio was determined between IL-1 and DMARD and was
found to be equal to 0.15. CONCLUSIONS: IL-1 inhibitor therapy is the most cost
effective for rheumatoid arthritis in western Indian population.
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OBJECTIVES: Examine improvement in physical function, HRQOL & work produc-
tivity in a subset of Asian patients from the golimumab (GLM) RA & AS trials.
METHODS: RA patients with inadequate response to MTX in GO-FORWARD
(N444) & AS patients despite NSAID/DMARDs in GO-RAISE (N356) were random-
ized to SC GLM (50or100mg) or placebo q4wks. At wk16, RA patients with 20%
improvement in tender & swollen joint count or AS patients with 20% improve-
ment in both total back pain &morning stiffness entered early escape (i.e.,placebo
received GLM 50mg & GLM 50 mg received GLM 100mg).Physical function was
assessed using HAQ (0-3) in RA & BASFI (0-10) in AS. HRQOL was assessed using
SF-36 PCS (0-100) & SF-36 MCS (0-100). Impact of disease on work productivity was
assessed using a productivity VAS (0-10). Clinically meaningful improvement was
defined as improvement of 0.25 point in HAQ, 2 points in BASFI or 5 points in
SF-36 PCS &MCS. RESULTS:At baseline, RA patients (N48) had amean HAQ score
of 1.35, & AS patients (N83) had a mean BASFI score of 3.25; PCS & MCS were 31.5
& 42.5, respectively, in RA, & 33.2 & 41.3 in AS; productivity VASwas 5.6 in RA & AS.
Compared to placeboMTX-treated RA patients (N22), GLMMTX-treated pa-
tients (N26) had greater mean improvement in HAQ (0.54 vs -0.01, p0.01), PCS
(7.9 vs -0.40, p0.01) & work productivity (-2.4 vs -0.4, p0.05), the change in MCS
wasnot statistically significant (3.0 vs 2.1, p0.05). Compared to placebo-treatedAS
patients (N17), GLM-treated patients (N66) had greater mean improvements in
BASFI (1.51 vs 0.28, p0.05), MCS (5.3 vs -1.1, p0.05) & work productivity (-2.9 vs
-0.9, p0.05); change in PCS was not statistically significant (9.0 vs 5.7,p0.05).
Greater proportions of RA patients in GLM group than placebo achieved clinically
meaningful improvement in HAQ (73.1% vs 30%, p0.01), PCS (61.5% vs 25%,
p0.01) & MCS (50% vs 35%,p0.31); in AS, similar trends in clinically meaningful
improvement in BASFI, PCS & MCS observed between groups. Improvements in
HAQ, BASFI, SF-36 & work productivity in GLM-treated patients were sustained
over wk52 and 104, & were consistent across populations (Asia vs non-Asia).
CONCLUSIONS: Patients from Asia with RA or AS treated with GLM demonstrated
improved physical function & HRQOL.
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OBJECTIVES: Rheumatoid arthritis (RA) has an extensive impact on quality of life
(QOL) in RA patients. The aim of this study was to determine the effects of func-
tional impairment, disease activity andduration of disease onQOL after controlling
other risk factors. METHODS: This was a cross-sectional study comprised of 230
consecutive patients with RA from a rheumatology clinic. Quality of life was mea-
sured using Taiwan version of short form of World Health Organization Quality of
Life (WHOQOL-BREF) questionnaire. Disease activity was assessed by the Disease
Activity Score 28 (DAS28), functional disability by theHealthAssessmentQuestion-
naire (HAQ). Data on demographics, duration of disease, and income level were
also collected. The QOL of the RA patients was compared with 229 age-, sex-,
marriage-, and education-matched healthy control patients taken from a national
survey in Taiwan. Multiple regression analyses were conducted to study predictors
for impairment of QOL. RESULTS: RA patients have significantly lower score in
physical and psychological domain compared with healthy population, but they
showed a higher score in the environment domain ofWHOQOL-BREF. After adjust-
ment of HAQ, age, and other factors, we foundDAS28 score and duration of disease
significantly affect the QOL on almost all four domains. CONCLUSIONS: Functional
impairment, disease activity and duration independently affect the QOL of RA
patients. Future outcome research must take account of all these factors.
PMS22
IMPROVEMENT ON QUALITY OF LIFE AND DAILY FUNCTION IN RHEUMATOID
ARTHRITIS PATIENTS TREATED WITH INFLIXIMAB IN CHINA
He DY1, Chen JW2, Bi LQ3, Wu LJ4, Lin J5, Wang NS6, Li JG7, Yue N7, Feng WW7
1Shanghai Guanghua Hospital of Rheumatoid Arthritis, Shanghai, China, 2No.2 Xiangya Hospital
of Central South University, Changsha, China, 3China-Japan Union Hospital of Jilin University,
Changchun, China, 4Sinkiang People’s Hospital, Urumchi, China, 5First Affiliated Hospital of
Zhejiang University, Hangzhou, China, 6Shanghai No.6 People’s Hospital, Shanghai, China,
7Johnson & Johnson, Beijing, China
OBJECTIVES: Rheumatoid Arthritis (RA) is a seriously debilitating disease affecting
37 in every 1000 adult populations in China.We assessed symptoms, functionality,
and quality of life in RA patients who are treated with Infliximab in China.
METHODS: Amulti-center study was conducted from June 2009 to October 2011 in
RA patients at 37 urban hospitals in 21 cities in China. Symptoms were measured
by morning stiffness, and pain Visual Analogue Scale (VAS) scores defined from 0
(no pain) to 100 (severe pain). The Health Assessment Questionnaire (HAQ) was
used to measure functional status (scores 0-3). Quality of life was measured by the
mental (MCS) and physical component summary (PCS) scores of the Short Form-12
(SF-12). Comparisons were made between patients who were treated Infliximab at
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baseline and follow ups (experienced-Infliximab group, EIG) and those who were
not treated with Infliximab at baseline but went on Infliximab treatment at the
followups (new-Infliximab group, NIG). RESULTS:Of the 427 RApatients, 48 (11.2%)
used Infliximab before, 83%were female, and the average agewas 45 years old. The
average duration of RA was 6 years, with almost 40% patients suffering RA more
than 5 years. At baseline, the mean scores reported from the patients in EIG were:
morning stiffness 31min, pain 45, HAQ 0.65, MCS 47 and PCS 38, which were all
significantly better than patients in NIG. After 14 weeks Infliximab treatment, NIG
patients improved significantly in morning stiffness (-55.6min), pain (-38.5), HAQ
(-0.6), MCS (-16.2) and PCS (-15.6) than baseline (all P0.0001). CONCLUSIONS: RA
patients using Infliximab have better quality of life and daily function activities
than those not using Infliximab before. Our findings also indicate that, it is essen-
tial to continue or initiate treatment with Infliximab to improve outcomes and
quality of life in RA patients in China.
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OBJECTIVES: To report results of HRQOL in Chinese patients with rheumatoid
arthritis (RA) and ankylosing spondylitis (AS). METHODS: Adult patients 18yrs
diagnosed with RA or AS were recruited through referrals by physicians in 11
cities(tier 1 and tier 2 level) in China: Beijing, Shanghai, Guangzhou, Tianjin, Wu-
han, Nanjing, Hangzhou, Shenyang, Chengdu, Taiyuan, and Shijiazhuang. Patients
should have worked and stayed in the city 1yr. Disease severity was classified as
mild, moderate and severe based on physician’s subjective assessment. A Chinese
version of the Short-Form(SF)-36 (version 2) was completed by patients. A norm-
based scoring system developed from Chinese population(Hong Kong) was used to
derive 8 subscales: physical functioning(PF), role-physical(RP), bodily pain(BP), gen-
eral health(GH), vitality(VT), social functioning(SF), role-emotional(RE), andmental
health(MH); and physical and mental component summary(PCS and MCS) scores.
Each score ranges from 0 to 100 with higher scores representing better HRQL.
Descriptive statistics are presented. RESULTS: Adult patients with RA(N250, 94
male and 156 female) and AS(N150, 81 male, 69 female) were enrolled and com-
pleted the SF-36 questionnaire. Overall, patients demonstrated low scores (50) in
all 8 SF-36 subscales, especially in PF (31.316.7 vs 32.415.1), BP(34.79.4 vs
35.08.1) and SF(33.613.3 vs 33.012.8), for RA vs AS, respectively. The PCS and
MCS scores were 35.510.4 and 45.310.4, respectively, in AS patients and
34.711.7 and 46.39.6, respectively, in RA patients. These scores decreased with
increase in disease severity and age, but remained consistent with no significant
differences between men and female. CONCLUSIONS: SF-36 scores in Chinese pa-
tients with RA or AS were lower compared to the general Chinese population with
chronic diseases including cardiovascular disease and diabetes, indicating major
impairment in HRQOL.
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OBJECTIVES: Cost-utility analysis is increasingly important to market access deci-
sions in a growing number of countries including Australia. The ability to attach
utility values to health states is an essential component of cost-utility analysis. The
primary aim of this review was to identify appropriate utility weights in rheuma-
toid arthritis (RA) in Australia. The review also aimed to evaluate existing quality of
life (QoL) measures used in RA and identify the key issues associated with the use
of these measures. METHODS: Systematic methods were used to search the Eng-
lish language literature for studies reporting health-related utilities for RA. The
literature search covered a wide range of electronic databases (EMBASE, Medline,
Cochrane Library), and included literature from the inception of database to Janu-
ary 2012. RESULTS: The search identified 28 studies: 2 from Australia and 26 from
other countries. Both Australian studies reported mean EQ-5D utility values for
Australian patients with RA. One of the Australian studies also found that the HAQ
scores explained more of the variance in the HUI3-derived than EQ-5D-derived
utility weights, and that RA-affected joint counts had negligible explanatory power
for patient utility. Review of the other 26 studies found that a variety of QoL instru-
ments were used. All instruments were found to be valid measures for QoL in
patients with RA and appeared to adequately discriminate across levels of RA
severity. Nevertheless, each instrument revealed strengths and weaknesses,
which prevented the recommendation of one instrument in favour of the other.
CONCLUSIONS: This review of utility weights for RA revealed a high level of un-
certainty about the evidence base that informs cost-utility analyses in this disease
area. There is no conclusive evidence to date as towhichmeasure is the best for use
in RA.
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OBJECTIVES: Despite the fact that non-benzodiazepine hypnotics (Z-drugs) are
beneficial for the short-termmanagement of insomnia, it is inconclusive about the
risk and benefit ratios of long-term use. The aim of this study was to examine the
medication use patterns of Z-drugs and its prescribers in a 2000-bedmedical center
in Taiwan. METHODS: We conducted the medication use evaluation study using
China Medical University Hospital (CMUH) in-house databases. During the whole
year of 2011, those CMUHoutpatients ever prescribedwith zolpidem and zopiclone
were of interest. Their prescription prevalence rate of Z-drugs, its average number
of defined daily dose (DDD), prescriber specialties and demographic characteristics
were examined using descriptive analyses. RESULTS: In 2011, 2,261 and 2,885 pa-
tients were ever prescribed with at least one prescription with zolpidem and zopi-
clone, respectively, in the outpatient units in CMUH. While more female were
prescribed with Z-drugs, 40% of zolpidem users and 32% of zopiclone users were
elderly. Within one year period, the average prescription number of zolpidem and
zolpiclone were 5.474.78 and 4.34.38, respectively. While the average durations
for each prescription were 257 days for zolpidem and 238 days for zolpiclone,
respectively. 25% of zolpidem users and zolpiclone users were prescribed 9 to 43
times and 6 to 52 times, respectively. The top three prescribers were neurologist,
cardiologist, and psychiatrist, which in total had accounted for 63.01% and 46.96%
of zolpidem and zolpiclone prescriber specialties, respectively. CONCLUSIONS:
There is a tendency to have long-termuse of zolpidemand zopiclone among CMUH
outpatients. Those common prescribers of Z-drugs should be warranted for its
consequences of long-term use, especially among the elderly.
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OBJECTIVES: Despite global advancements in disease reporting, the epidemiology
of multiple sclerosis (MS) in Asia is not well reported. MS rates in Asia are low
compared to Europe and North America, but are now thought to be increasing.
Globally, themedian prevalence ofMS is 30/100,000. Our goal is a systematic search
of epidemiologic studies of MS in Asia to determine accurate epidemiologic and
treatment cost estimates. METHODS: This systematic review examined articles
published in English over 20 years using MESH terms: MS, incidence, prevalence,
mortality and costs in any Asian country. Articles with evidence from population-
based samples, based on clinically-defined or laboratory supported MS (e.g., Mc-
Donald criteria) diagnoses, and from major Asian countries were retained. Costs
were the 2008 estimates from the Global Economic Impact of MS. RESULTS: As in
other continents, prevalence in Asia is higher in women than men. In the largest
country, China, prevalence rates of MS are low (1-2/100,000). In Northern Japan, a
much higher prevalence (8.6/100,000) was reported in 2002, an increase from 2.5 in
1975. In Korea, with a population density similar to China, the prevalence was
3.5/100,000, similar to the 3.0/100,000 in Taiwan (2005). Based on an annual cost per
patient of $41,335 (USD international), 2008 estimated costs in China due to MS
exceed $1 billion. In Japan, with 10 times fewer people, the costs exceed $452
million. CONCLUSIONS:Data frommany Asian countries is limited and often from
case-series designed to review clinical characteristics. Larger epidemiological and
cost-based studies in various populations are still needed. Recent evidence sug-
gests a higher prevalence than previously thought, possibly a result of better as-
certainment driven by increased diagnostic awareness. This review supports the
development of effective medications and additional research to better under-
stand the unmet medical need and economic burden driven by MS in Asia.
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OBJECTIVES: Prolonged-release (PR) fampridine is a first-in-class treatment for the
management of walking disability in multiple sclerosis (MS). The purpose of this
study was to evaluate the budget impact of PR-fampridine introduction in the
treatment of MS patients with an Expanded Disability Severity Scale (EDSS) score
between 4.0 and 7.0 in Taiwan.METHODS: A budget impact model was developed
with amonthly cycle Markov-chain to evaluate the cost implications of PR-fampri-
dine use to the Taiwan health care payer. All costs in themodel were sourced from
the Taiwan National Health Insurance formulary and are presented in Taiwan
dollars (NT$). Response rates of 35% and 43%, derived frompivotal Phase III trials of
PR-fampridine, were applied. The budget impact was calculated for a 5-year time
horizon. The base case analysis included the treatment costs of PR-fampridine
only. Sensitivity analyseswere conducted on the impact of PR-fampridine on direct
costs and on market share. RESULTS: For the year 2012, the model estimated 79
patients with EDSS between 4.0 and 7.0 and walking impairment eligible for PR-
fampridine treatment. Budget impact after the introduction of PR-fampridine us-
ing a patient response rate of 35% was NT$241,000 rising to NT$3,225,000 over the
5-year time horizon. Applying a 43% response rate resulted in a budget impact of
NT$285,000 in 2012which equates to a 3.61% increase in spending. CONCLUSIONS:
Walking difficulty is one of themost commonly reported disabilities inMS patients
and PR-fampridine is the only medication indicated for symptom alleviation. The
introduction of PR-fampridine leads to a manageable budget impact in Taiwan as
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